ZNF224 and chronic myelogenous leukemia, BCR-ABL1 positive: On the contrary, in CML, where the expression of ZNF224 is usually silenced, the treatment with ara-C, imatinib, and tyrosine kinase inhibitors increased ZNF224 expression, resulting in enhanced apoptosis, better treatment response, and improved patient prognosis [147,149,150].